<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00981526</url>
  </required_header>
  <id_info>
    <org_study_id>2008-P-000790</org_study_id>
    <nct_id>NCT00981526</nct_id>
  </id_info>
  <brief_title>Telmisartan as an Adjunctive Treatment for Metabolic Problems in Patients With Schizophrenia</brief_title>
  <official_title>Telmisartan as an Adjunctive Treatment for Metabolic Problems in Patients With Schizophrenia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Massachusetts, Worcester</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institutes of Health (NIH)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Massachusetts, Worcester</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a 12-week, randomized, double-blinded, placebo-controlled trial of telmisartan 80
      mg/day as an adjunctive to clozapine or olanzapine therapy, in 70 schizophrenia subjects to
      examine telmisartan's effect on glucose metabolism, weight, food intake, resting energy
      expenditure, and body composition. In addition, the study will examine insulin's effects on
      psychopathology and cognition.

      Potential subjects will be identified by their clinicians at the Freedom Trail Clinic, or
      Massachusetts General Hospital. Approximately 70 subjects will be enrolled.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The specific aims include:

      Primary Aims:

        1. Examine the efficacy of telmisartan added to regular doses of clozapine or olanzapine in
           improving insulin resistance.

        2. Examine the efficacy of telmisartan in reducing fasting triglycerides.

      Secondary Aims:

        1. Examine the effects of telmisartan on negative symptoms, positive symptoms, and
           cognitive function.

        2. Examine the efficacy of telmisartan in improving glucose metabolism as measured by
           glucose effectiveness (SG) and the acute insulin response to glucose (AIRG).

        3. Examine telmisartan's effects on lipids, body composition, waist circumference, and
           waist/hip ratio.

        4. Examine telmisartan's effects on weight, food intake and resting energy expenditure.

        5. Characterize the relationships between changes in CRP, IL-6, and changes in fasting
           insulin and glucose, SI, SG, and AIRG from FSIVGTT.

        6. Characterize the relationships between changes in fasting insulin and glucose, SI, SG,
           and AIRG from FSIVGTT, CRP, IL-6, and changes in negative symptoms, positive symptoms
           and cognitive function.

        7. Examine telmisartan's effects on inflammatory biomarkers including C-reactive protein
           (CRP) and interleukin 6 (IL-6).
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2009</start_date>
  <completion_date type="Actual">May 2012</completion_date>
  <primary_completion_date type="Actual">May 2012</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Metabolism, weight, food intake, energy, and body composition</measure>
    <time_frame>12 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cognition and psychopathology</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">57</enrollment>
  <condition>Schizophrenia</condition>
  <condition>Schizoaffective Disorder</condition>
  <arm_group>
    <arm_group_label>A: Experimental</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>(existing Clozapine or Olanzapine treatment) + (Drug)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B: Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>(existing Clozapine or Olanzapine treatment) + (Placebo)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Telmisartan</intervention_name>
    <description>Telmisartan (plus existing clozapine or olanzapine treatment) 40mg/day for the first 2 weeks.
Telmisartan (plus existing clozapine or olanzapine treatment) 80mg/day for the next 10 weeks.</description>
    <arm_group_label>A: Experimental</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo (plus existing clozapine or olanzapine treatment) for 12 weeks.</description>
    <arm_group_label>B: Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Clozapine</intervention_name>
    <description>Clozapine (plus telmisartan or placebo) for 12 weeks.</description>
    <arm_group_label>A: Experimental</arm_group_label>
    <arm_group_label>B: Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Olanzapine</intervention_name>
    <description>Olanzapine (plus telmisartan or placebo) for 12 weeks.</description>
    <arm_group_label>A: Experimental</arm_group_label>
    <arm_group_label>B: Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Age 18-65 years

          2. Diagnosis of schizophrenia, any subtype or schizoaffective disorder, any subtype

          3. Treatment with clozapine or olanzapine for at least 6 months

          4. Stable dose of antipsychotic agent for at least one month

          5. Well establish compliance with out-patient medications

          6. Females subjects will be eligible to participate in the study if they are of
             non-childbearing potential or of child-bearing potential and willing to practice
             appropriate birth control methods (complete abstinence from sexual intercourse, female
             sterilization, sterilization of male partner, implants of levonorgestrel, injectable
             progestogen, oral contraceptives, intrauterine devices, or double barrier methods of
             contraception using spermicide with either a condom or diaphragm) during the study.

        Exclusion Criteria:

          1. Inability to provide informed consent

          2. Current substance abuse

          3. Psychiatrically unstable

          4. Significant medical illness including severe cardiovascular, hepatic, renal disease

          5. Current insulin treatment of diabetes

          6. History of immunosuppression

          7. Current or recent radiation or chemotherapy treatment for cancer

          8. Chronic use of steroids

          9. Pregnancy or breast feeding

         10. Use of diuretics, digoxin, warfarin because the possible drug-drug interaction of
             telmisartan
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Xiaoduo Fan, MD, MPH, MS</last_name>
    <role>Principal Investigator</role>
    <affiliation>UMass Medical School</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Massachusetts Medical School</name>
      <address>
        <city>Worcester</city>
        <state>Massachusetts</state>
        <zip>01605</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 18, 2009</study_first_submitted>
  <study_first_submitted_qc>September 21, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 22, 2009</study_first_posted>
  <disposition_first_submitted>June 19, 2013</disposition_first_submitted>
  <disposition_first_submitted_qc>July 24, 2013</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">July 31, 2013</disposition_first_posted>
  <last_update_submitted>August 12, 2013</last_update_submitted>
  <last_update_submitted_qc>August 12, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 21, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Massachusetts, Worcester</investigator_affiliation>
    <investigator_full_name>Xiaoduo Fan</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Schizophrenia</keyword>
  <keyword>Cognition</keyword>
  <keyword>Metabolism</keyword>
  <keyword>Antipsychotics</keyword>
  <keyword>Psychopathology</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Schizophrenia</mesh_term>
    <mesh_term>Psychotic Disorders</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Olanzapine</mesh_term>
    <mesh_term>Clozapine</mesh_term>
    <mesh_term>Telmisartan</mesh_term>
  </intervention_browse>
  <pending_results>
    <submitted>October 20, 2016</submitted>
    <returned>December 14, 2016</returned>
    <submitted>April 5, 2018</submitted>
    <returned>May 7, 2018</returned>
    <submitted>May 21, 2018</submitted>
  </pending_results>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

